Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer

TEXT and SOFT trials

Meredith M. Regan, Olivia Pagani, Prudence A. Francis, Gini F. Fleming, Barbara A. Walley, Roswitha Kammler, Patrizia Dell’Orto, Leila Russo, János Szőke, Franco Doimi, Laura Villani, Stefano Pizzolitto, Christian Öhlschlegel, Fausto Sessa, Vicente Peg Cámara, José Luis Rodríguez Peralto, Gaëtan MacGrogan, Marco Colleoni, Aron Goldhirsch, Karen N. Price & 3 others Alan S. Coates, Richard D. Gelber, Giuseppe Viale

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The SOFT and TEXT randomized phase III trials investigated adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR+) early breast cancer. We investigated the prognostic and predictive value of centrally assessed levels of estrogen receptor (ER), progesterone receptor (PgR), and Ki-67 expression in women with HER2-negative disease. Of 5707 women enrolled, 4115 with HER2-negative (HR+/HER2−) disease had ER, PgR, and Ki-67 centrally assessed by immunohistochemistry. Breast cancer-free interval (BCFI) was defined from randomization to first invasive local, regional, or distant recurrence or contralateral breast cancer. The prognostic and predictive values of ER, PgR and Ki-67 expression levels were assessed using Cox modeling and STEPP methodology. In this HR+/HER2- population, the median ER, PgR, and Ki-67 expressions were 95, 90, and 18 % immunostained cells. As most patients had strongly ER-positive tumors, the predictive value of ER levels could not be investigated. Lower PgR and higher Ki-67 expression were associated with reduced BCFI. There was no consistent evidence of heterogeneity of the relative treatment effects according to PgR or Ki-67 expression levels, though there was a greater 5-year absolute benefit of exemestane + ovarian function suppression (OFS) versus tamoxifen with or without OFS at lower levels of PgR and higher levels of Ki-67. Women with poor prognostic features of low PgR and/or high Ki-67 have greater absolute benefit from exemestane + OFS versus tamoxifen + OFS or tamoxifen alone, but individually PgR and Ki-67 are of limited predictive value for selecting adjuvant endocrine therapy for premenopausal women with HR+/HER2− early breast cancer.

Original languageEnglish
Pages (from-to)275-286
Number of pages12
JournalBreast Cancer Research and Treatment
Volume154
Issue number2
DOIs
Publication statusPublished - Nov 1 2015

Fingerprint

Progesterone Receptors
Estrogen Receptors
Hormones
Breast Neoplasms
exemestane
Tamoxifen
Therapeutics
Random Allocation
Immunohistochemistry
Recurrence

Keywords

  • Estrogen receptor
  • Exemestane
  • Ki-67
  • Ovarian function suppression
  • Progesterone receptor
  • Tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer : TEXT and SOFT trials. / Regan, Meredith M.; Pagani, Olivia; Francis, Prudence A.; Fleming, Gini F.; Walley, Barbara A.; Kammler, Roswitha; Dell’Orto, Patrizia; Russo, Leila; Szőke, János; Doimi, Franco; Villani, Laura; Pizzolitto, Stefano; Öhlschlegel, Christian; Sessa, Fausto; Peg Cámara, Vicente; Rodríguez Peralto, José Luis; MacGrogan, Gaëtan; Colleoni, Marco; Goldhirsch, Aron; Price, Karen N.; Coates, Alan S.; Gelber, Richard D.; Viale, Giuseppe.

In: Breast Cancer Research and Treatment, Vol. 154, No. 2, 01.11.2015, p. 275-286.

Research output: Contribution to journalArticle

Regan, MM, Pagani, O, Francis, PA, Fleming, GF, Walley, BA, Kammler, R, Dell’Orto, P, Russo, L, Szőke, J, Doimi, F, Villani, L, Pizzolitto, S, Öhlschlegel, C, Sessa, F, Peg Cámara, V, Rodríguez Peralto, JL, MacGrogan, G, Colleoni, M, Goldhirsch, A, Price, KN, Coates, AS, Gelber, RD & Viale, G 2015, 'Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials', Breast Cancer Research and Treatment, vol. 154, no. 2, pp. 275-286. https://doi.org/10.1007/s10549-015-3612-z
Regan, Meredith M. ; Pagani, Olivia ; Francis, Prudence A. ; Fleming, Gini F. ; Walley, Barbara A. ; Kammler, Roswitha ; Dell’Orto, Patrizia ; Russo, Leila ; Szőke, János ; Doimi, Franco ; Villani, Laura ; Pizzolitto, Stefano ; Öhlschlegel, Christian ; Sessa, Fausto ; Peg Cámara, Vicente ; Rodríguez Peralto, José Luis ; MacGrogan, Gaëtan ; Colleoni, Marco ; Goldhirsch, Aron ; Price, Karen N. ; Coates, Alan S. ; Gelber, Richard D. ; Viale, Giuseppe. / Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer : TEXT and SOFT trials. In: Breast Cancer Research and Treatment. 2015 ; Vol. 154, No. 2. pp. 275-286.
@article{d692add44d8346fdaf5611b703038690,
title = "Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials",
abstract = "The SOFT and TEXT randomized phase III trials investigated adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR+) early breast cancer. We investigated the prognostic and predictive value of centrally assessed levels of estrogen receptor (ER), progesterone receptor (PgR), and Ki-67 expression in women with HER2-negative disease. Of 5707 women enrolled, 4115 with HER2-negative (HR+/HER2−) disease had ER, PgR, and Ki-67 centrally assessed by immunohistochemistry. Breast cancer-free interval (BCFI) was defined from randomization to first invasive local, regional, or distant recurrence or contralateral breast cancer. The prognostic and predictive values of ER, PgR and Ki-67 expression levels were assessed using Cox modeling and STEPP methodology. In this HR+/HER2- population, the median ER, PgR, and Ki-67 expressions were 95, 90, and 18 {\%} immunostained cells. As most patients had strongly ER-positive tumors, the predictive value of ER levels could not be investigated. Lower PgR and higher Ki-67 expression were associated with reduced BCFI. There was no consistent evidence of heterogeneity of the relative treatment effects according to PgR or Ki-67 expression levels, though there was a greater 5-year absolute benefit of exemestane + ovarian function suppression (OFS) versus tamoxifen with or without OFS at lower levels of PgR and higher levels of Ki-67. Women with poor prognostic features of low PgR and/or high Ki-67 have greater absolute benefit from exemestane + OFS versus tamoxifen + OFS or tamoxifen alone, but individually PgR and Ki-67 are of limited predictive value for selecting adjuvant endocrine therapy for premenopausal women with HR+/HER2− early breast cancer.",
keywords = "Estrogen receptor, Exemestane, Ki-67, Ovarian function suppression, Progesterone receptor, Tamoxifen",
author = "Regan, {Meredith M.} and Olivia Pagani and Francis, {Prudence A.} and Fleming, {Gini F.} and Walley, {Barbara A.} and Roswitha Kammler and Patrizia Dell’Orto and Leila Russo and J{\'a}nos Szőke and Franco Doimi and Laura Villani and Stefano Pizzolitto and Christian {\"O}hlschlegel and Fausto Sessa and {Peg C{\'a}mara}, Vicente and {Rodr{\'i}guez Peralto}, {Jos{\'e} Luis} and Ga{\"e}tan MacGrogan and Marco Colleoni and Aron Goldhirsch and Price, {Karen N.} and Coates, {Alan S.} and Gelber, {Richard D.} and Giuseppe Viale",
year = "2015",
month = "11",
day = "1",
doi = "10.1007/s10549-015-3612-z",
language = "English",
volume = "154",
pages = "275--286",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "2",

}

TY - JOUR

T1 - Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer

T2 - TEXT and SOFT trials

AU - Regan, Meredith M.

AU - Pagani, Olivia

AU - Francis, Prudence A.

AU - Fleming, Gini F.

AU - Walley, Barbara A.

AU - Kammler, Roswitha

AU - Dell’Orto, Patrizia

AU - Russo, Leila

AU - Szőke, János

AU - Doimi, Franco

AU - Villani, Laura

AU - Pizzolitto, Stefano

AU - Öhlschlegel, Christian

AU - Sessa, Fausto

AU - Peg Cámara, Vicente

AU - Rodríguez Peralto, José Luis

AU - MacGrogan, Gaëtan

AU - Colleoni, Marco

AU - Goldhirsch, Aron

AU - Price, Karen N.

AU - Coates, Alan S.

AU - Gelber, Richard D.

AU - Viale, Giuseppe

PY - 2015/11/1

Y1 - 2015/11/1

N2 - The SOFT and TEXT randomized phase III trials investigated adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR+) early breast cancer. We investigated the prognostic and predictive value of centrally assessed levels of estrogen receptor (ER), progesterone receptor (PgR), and Ki-67 expression in women with HER2-negative disease. Of 5707 women enrolled, 4115 with HER2-negative (HR+/HER2−) disease had ER, PgR, and Ki-67 centrally assessed by immunohistochemistry. Breast cancer-free interval (BCFI) was defined from randomization to first invasive local, regional, or distant recurrence or contralateral breast cancer. The prognostic and predictive values of ER, PgR and Ki-67 expression levels were assessed using Cox modeling and STEPP methodology. In this HR+/HER2- population, the median ER, PgR, and Ki-67 expressions were 95, 90, and 18 % immunostained cells. As most patients had strongly ER-positive tumors, the predictive value of ER levels could not be investigated. Lower PgR and higher Ki-67 expression were associated with reduced BCFI. There was no consistent evidence of heterogeneity of the relative treatment effects according to PgR or Ki-67 expression levels, though there was a greater 5-year absolute benefit of exemestane + ovarian function suppression (OFS) versus tamoxifen with or without OFS at lower levels of PgR and higher levels of Ki-67. Women with poor prognostic features of low PgR and/or high Ki-67 have greater absolute benefit from exemestane + OFS versus tamoxifen + OFS or tamoxifen alone, but individually PgR and Ki-67 are of limited predictive value for selecting adjuvant endocrine therapy for premenopausal women with HR+/HER2− early breast cancer.

AB - The SOFT and TEXT randomized phase III trials investigated adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR+) early breast cancer. We investigated the prognostic and predictive value of centrally assessed levels of estrogen receptor (ER), progesterone receptor (PgR), and Ki-67 expression in women with HER2-negative disease. Of 5707 women enrolled, 4115 with HER2-negative (HR+/HER2−) disease had ER, PgR, and Ki-67 centrally assessed by immunohistochemistry. Breast cancer-free interval (BCFI) was defined from randomization to first invasive local, regional, or distant recurrence or contralateral breast cancer. The prognostic and predictive values of ER, PgR and Ki-67 expression levels were assessed using Cox modeling and STEPP methodology. In this HR+/HER2- population, the median ER, PgR, and Ki-67 expressions were 95, 90, and 18 % immunostained cells. As most patients had strongly ER-positive tumors, the predictive value of ER levels could not be investigated. Lower PgR and higher Ki-67 expression were associated with reduced BCFI. There was no consistent evidence of heterogeneity of the relative treatment effects according to PgR or Ki-67 expression levels, though there was a greater 5-year absolute benefit of exemestane + ovarian function suppression (OFS) versus tamoxifen with or without OFS at lower levels of PgR and higher levels of Ki-67. Women with poor prognostic features of low PgR and/or high Ki-67 have greater absolute benefit from exemestane + OFS versus tamoxifen + OFS or tamoxifen alone, but individually PgR and Ki-67 are of limited predictive value for selecting adjuvant endocrine therapy for premenopausal women with HR+/HER2− early breast cancer.

KW - Estrogen receptor

KW - Exemestane

KW - Ki-67

KW - Ovarian function suppression

KW - Progesterone receptor

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=84947611492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947611492&partnerID=8YFLogxK

U2 - 10.1007/s10549-015-3612-z

DO - 10.1007/s10549-015-3612-z

M3 - Article

VL - 154

SP - 275

EP - 286

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -